The CASABLANCA Study: Catheter Sampled Blood Archive in Cardiovascular Diseases
NCT00842868 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1298
Last updated 2016-09-19
Summary
The purpose of this research is to determine the relationship between novel blood tests for heart function (including hormones and heart enzymes measured in the blood), and assess for kidney damage before and after angiography (cardiac catheterization). We hypothesize that these novel tests will enable us to predict possible complications of catheterization immediately after the procedure.
Conditions
- Atherosclerosis
- Contrast Induced Nephropathy
- Renal Impairment
Sponsors & Collaborators
-
Massachusetts General Hospital
lead OTHER
Principal Investigators
-
James L Januzzi, MD · Massachusetts General Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2015-03-31
- Completion
- 2015-03-31
Countries
- United States
Study Locations
More Related Trials
-
Prevention of Contrast-induced Nephropathy in Patients With Acute Myocardial Infarction
NCT01160627 ·Status: COMPLETED ·Phase: NA
-
Using Preprocedural Urine NMR(Nuclear Magnetic Resonance) -Based Metabolomics Analysis
NCT03731962 ·Status: COMPLETED ·Phase: NA
-
Development of a Biomarker Panel for the Earlier Prediction of Acute Kidney Injury in Patients With Diabetes
NCT00948116 ·Status: RECRUITING
-
Renal PRotection Against Contrast mEdium-induced nephroPathy in High Risk Patients undErgoing Coronary Angiography
NCT02463604 ·Status: COMPLETED ·Phase: NA
-
Contrast Induced Nephropathy Among Vascular Patients Undergoing Lower Limb Angioplasty
NCT04879186 ·Status: UNKNOWN
-
Arginase Inhibition in Ischemia-reperfusion Injury
NCT02009527 ·Status: COMPLETED ·Phase: PHASE1
-
Carotid Doppler Screening for Subclinical Atherosclerosis in Diabetic CKD Patients.
NCT07266220 ·Status: NOT_YET_RECRUITING
-
Effect of Homocysteine and Asymmetric Dimethylarginine on Cardiovascular Events in Hemodialysis Patients
NCT00161369 ·Status: COMPLETED
-
The Effect of Whole Blood Viscosity on Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention
NCT04703049 ·Status: COMPLETED
-
N-acetylcysteine to Prevent Renal Failure
NCT01359722 ·Status: UNKNOWN ·Phase: NA
-
Safe Use of Heparin Sodium in Patients With Chronic Renal Failure.
NCT01229072 ·Status: SUSPENDED ·Phase: PHASE2/PHASE3
-
Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation
NCT06695429 ·Status: RECRUITING ·Phase: NA
-
Normobaric Hyperoxygenation for Prevention of Contrast Induced Nephropathy
NCT01448889 ·Status: UNKNOWN ·Phase: NA
-
Renal Effect of Pentoxyphylline in High Risk Patients Undergoing Angiography
NCT01144091 ·Status: WITHDRAWN ·Phase: NA
-
Prevention of Serious Adverse Events Following Angiography
NCT01467466 ·Status: COMPLETED ·Phase: PHASE3
-
Renal Acute MI Study
NCT01580566 ·Status: COMPLETED
-
Remote Ischemic Preconditioning as a Method Against Subclinical Renal Injury and Contrast-induced Nephropathy
NCT02700958 ·Status: COMPLETED ·Phase: NA
-
Red Blood Cell Distribution Width as a Marker of Contrast Induced Nephropathy in Patients With Coronary Intervention
NCT03164681 ·Status: UNKNOWN
-
Sodium Bicarbonate and N-Acetylcysteine for Nephroprotection in Acute Myocardial Infarction
NCT01218178 ·Status: COMPLETED
-
Effect of Remote Ischemic Preconditioning on the Incidence of Contrast Induced Nephropathy in Patients Undergoing EVAR
NCT05350683 ·Status: COMPLETED ·Phase: PHASE2
-
The Use of Inorganic Nitrate for the Prevention of Contrast-induced Nephropathy
NCT03627130 ·Status: COMPLETED ·Phase: PHASE2
-
Trial for Prevention of Contrast Nephropathy With Sodium Bicarbonate
NCT00312117 ·Status: COMPLETED ·Phase: PHASE3
-
AV Fistula Salvage in Advanced CKD Using Sodium Bicarbonate Prophylaxis
NCT00621972 ·Status: WITHDRAWN
-
Prevention of Contrast Renal Injury With Different Hydration Strategies
NCT01218828 ·Status: COMPLETED ·Phase: PHASE3
-
Dapagliflozin to Prevent the Incidence of Contrast Induced Nephropathy After Heart Catheterization and Percutaneous Coronary Intervention
NCT04806633 ·Status: UNKNOWN ·Phase: EARLY_PHASE1